Eversana partners on research data assessment

By Jenni Spinner contact

- Last updated on GMT

(Panuwat Sikham/iStock via Getty Images Plus)
(Panuwat Sikham/iStock via Getty Images Plus)

Related tags: Eversana, Clinical research, Data management, analytics

The company is joining with ICER to help promote use of robust, repeatable indirect comparisons in health tech assessments.

Research nonprofit the Institute for Clinical and Economic Review (ICER) is partnering with life-sciences global commercial services firm Eversana. The collaboration is geared toward advancing standards for usage of “transparent, replicable and robust” indirect treatment comparisons used in health technology assessments, according to Eversana.

ICER is an nonprofit research institute with the mission of producing drug assessments and other reviews covering the comparative clinical effectiveness, as well as cost effectiveness, of health-care interventions. ICER reportedly will use Eversana’s technology platform to conduct indirect treatment comparisons to cull comparative effectiveness data, outside of head-to-head clinical trials; the organization started testing the platform earlier this year.

Eversana’s platform will make us more efficient in how we conduct high-quality and reproducible indirect treatment comparisons​,” said Foluso Agboola, director of evidence Synthesis for ICER. “They’ve built a best-in-class technology that will help us advance many ongoing initiatives across the U.S. and further support our mission​.”

Chris Cameron, senior vice president of data analytics and evidence synthesis at Eversana, said the joint effort between ICER and his company shows “the continued need for novel methods and technology to assess comparative effectiveness of treatments in the absence of clinical trials​."

Together we’ll continue to advance methods and technology for conducting world-class comparative clinical assessments that will help bring new medical treatments to patients in need​,” he added.

The web-based platform Eversana combines advanced indirect comparison methods with computing technology to indirectly compare treatments that have not been compared directly in clinical trials. The technology reportedly can incorporate both clinical trial and real-world data, with transparent methods scientifically validated by global experts and benchmarked against standards set by health technology assessment agencies, payers and regulatory bodies.

According to Eversana, the collaboration builds on both entities’ commitment to advancing application and transparency of indirect treatment comparison methods. In late 2019, Eversana acquired Canada-based Cornerstone Research Group, a provider of indirect treatment comparisons and HEOR services. It also launched its data and analytics business unit in April 2020.

ICER reportedly plans to continue its work in leveraging indirect treatment comparisons to complement other sources of information used in its value assessments. It intends to continue its mission of supporting fair pricing, fair access and future innovation across the US health care system.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 18-Jul-2022 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

Planning Your First-In-Human Trial

Planning Your First-In-Human Trial

Altasciences | 15-Jul-2022 | Technical / White Paper

A first-in-human (FIH) clinical trial is a significant milestone in the development of a potential new drug. A successfully conducted FIH trial provides...

Related suppliers

Follow us


View more